Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer

The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.

Inclusion Criteria:

• Male of 20 years or above
• Subject with prostate cancer with TNM stage T2~4NxMx
• Blood testosterone concentration ≥ 100ng/dl
• Bilirubin ≤ 1.5xULN, transaminase ≤ 2.5xULN
• WHO ECOG performance status ≤ 2
• Signed written informed consent

Exclusion Criteria:

• Hormone-Refractory Prostate cancer
• Brain metastasis
• Another primary malignant tumor except for prostate cancer
• Other conditions which in the opinion of the investigator preclude enrollment into the study